{"id":11934,"date":"2022-04-05T16:31:52","date_gmt":"2022-04-05T13:31:52","guid":{"rendered":"https:\/\/roboforex.com\/blog\/?p=11934"},"modified":"2024-04-15T13:52:02","modified_gmt":"2024-04-15T10:52:02","slug":"ipo-of-qsam-biosciences-attempt-to-beat-cancer","status":"publish","type":"post","link":"https:\/\/roboforex.com\/blog\/2022\/04\/05\/ipo-of-qsam-biosciences-attempt-to-beat-cancer\/","title":{"rendered":"IPO of QSAM Biosciences: Attempt to Beat Cancer"},"content":{"rendered":"\n

Modern medicine has found effective cures for many severe diseases. Unfortunately, in most cases to this day, cancer diseases remain a death sentence for millions of people.<\/p>\n\n\n\n

Scientists from all over the world keep on trying to develop a medicine that will help to beat cancer and it is important to emphasize that they managed to make massive progress on that.<\/p>\n\n\n\n

\"IPO<\/a><\/figure>\n\n\n\n

Today, we’ll talk about QSAM Biosciences, the company that developed medicine for marrow cancer treatment. QSAM Biosciences is planning to go public on 7 April by listing on the NASDAQ under the \"QSAM\" ticker symbol. Let’s study the issuer’s business and try to find out whether the stock<\/a> might find its audience among investors.<\/p>\n\n\n\n

<\/span><\/a>The business of QSAM Biosciences<\/span><\/h2>\n\n\n\n

QSAM Biosciences Inc. was founded in 2004 with headquarters in Austin, Texas. The company develops new generation radiopharmaceutical medicines for cancer treatment based on the application of Samarium 153. The research has shown that this isotope proved to be effective against metastases in the bone marrow and other affected organs.<\/p>\n\n\n\n

\"CycloSam<\/a>
CycloSam trial phases<\/em><\/figcaption><\/figure>\n\n\n\n

The issuer’s pharmaceutical development named CycloSam is an advanced modification of Quadramet, the medicine approved by the US Food and Drug Administration (FDA<\/a>) earlier.<\/p>\n\n\n\n

CycloSam uses the same radioisotope, Samarium 153, along with DOTMP. They are a basis for mono and combined therapy for treating marrow cancer.<\/p>\n\n\n\n

\"Additional<\/a>
Additional information on CycloSam<\/em><\/figcaption><\/figure>\n\n\n\n

Last August, QSAM Biosciences applied to the FDA to register CycloSam. During the first trial stage, they analysed the action of the medicine on metastases in the lungs, lactiferous glands, prostate, and other body organs.<\/p>\n\n\n\n

CycloSam was granted the orphan status for treating kids and teenagers with marrow cancer. First patients took part in the research at the beginning of March. This phase might take from 12 to 24 months – it depends on the dynamics of positive results.<\/p>\n\n\n\n

In March 2020, CycloSam was successfully used in the experimental treatment of an ER patient in Cleveland. The medicine has a shorter biological half-life and is faster eliminated from the body.<\/p>\n\n\n\n

<\/span><\/a>What are the prospects of QSAM Biosciences’ target market?<\/span><\/h2>\n\n\n\n

According to Insight Partners, the radiopharmaceutical medicine market in 2021 was estimated at $7.6 billion. It is expected to reach $13.8 billion by 2028.<\/p>\n\n\n\n

\"Target<\/a>
Target market of QSAM Biosciences in the US<\/em><\/figcaption><\/figure>\n\n\n\n

70% of patients with bone metastasis incur higher risks of bone fractures and spinal cord compression. In the US, they spend $12.7 billion on fighting metastatic cancer. Unfortunately, this type of cancer is considered incurable.<\/p>\n\n\n\n

<\/span><\/a>Financial performance of QSAM Biosciences<\/span><\/h2>\n\n\n\n

The issuer doesn’t generate any revenue because its major medicine is undergoing clinical trials. According to the provided report, clinical trials expenses in 2021 were $11.04 million. This indicator has grown exponentially.<\/p>\n\n\n\n

\"Financial<\/a>
Financial performance of QSAM Biosciences<\/em><\/figcaption><\/figure>\n\n\n\n

Most of the company’s expenses, about 75%, fall on covering operational costs. However, that makes sense since QSAM Biosciences is actively preparing to start mass production of its medicine. It is also worthy of note that the company’s management reduced administrative costs by 16% and increased expenses on development and research by 78%.<\/p>\n\n\n\n

As of now, the issuer’s total liabilities are $1.67 million, and the cash equivalents on its balance sheet are $1.46 million<\/p>\n\n\n\n

<\/span><\/a>Strengths and weaknesses of QSAM Biosciences<\/span><\/h2>\n\n\n\n

The company’s strengths are:<\/p>\n\n\n\n